返回 
加入收藏
不同剂量阿托伐他汀对慢性硬膜下血肿的疗效及安全性评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 不同剂量阿托伐他汀对慢性硬膜下血肿的疗效及安全性评价 |
| TITLE： | |
| 摘要： | 目的：观察不同剂量的阿托伐他汀对慢性硬膜下血肿（CSDH）患者的临床疗效和安全性。方法：选择2013年6月－2015年5月我院CSDH患者128例，按照随机数字表法分为观察组（n＝62）和对照组（n＝66）。所有患者均给予常规的脑细胞营养治疗；对照组患者给予阿托伐他汀钙片20 mg，po，qd；观察组患者给予阿托伐他汀钙片40 mg，po，qd。两组患者均连续治疗6个月。观察两组患者的临床疗效、神经功能缺损评分标准（CSS）及日常生活能力量表（ADL）评分、血肿量和血清炎症因子[超敏C反应蛋白（hs-CRP）、基质金属蛋白酶9（MMP-9）、白细胞介素6（IL-6）和肿瘤坏死因子α（TNF-α）]水平，记录治疗过程中的不良反应及治疗后6个月内的复发率。结果：观察组患者脱落2例，对照组患者脱落6例，最终纳入统计的合格病例为120例，两组各60例。观察组患者总有效率（88.3％）明显优于对照组（73.3％），差异有统计学意义（P＜0.05）。治疗后1、3、6个月，两组患者CSS评分、血肿量和血清hs-CRP、MMP-9、IL-6、TNF-α水平明显降低，ADL评分明显升高，且观察组患者上述指标改善程度明显优于对照组，差异均有统计学意义（P＜0.05）。两组患者各项不良反应的发生率比较，差异均无统计学意义（P＞0.05）。对照组患者的复发率（13.3％）明显高于观察组（3.3％），差异有统计学意义（P＜0.05）。结论：阿托伐他汀40 mg的日剂量对CSDH患者的临床疗效更好、复发率更低，且安全性良好。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy and safety of different doses of atorvastatin in the treatment of chronic subdural hematoma （CSDH）. METHODS： One hundred and tweaty-eight CSDH patients selected from our hospital during Jun. 2013-May 2015 were divided into observation group （n＝62） and control group （n＝66） in accordance with random number table. Both groups were given conventional treatment of brain cell nutrition. Control group received Atorvastatin tablet 20 mg， po， qd； observation group received Atorvastatin tablet 40 mg， po， qd. Both groups were treated for 6 months. Clinical efficacy， CSS and ADL score， hematoma volume， the levels of serum inflammatory factors （hs-CRP， MMP-9， IL-6， TNF-α） were observed in 2 groups. ADR was recorded during treatment and recurrence rate was also recorded. RESULTS： Two patients withdrew from observation group and 6 from control group. Finally， 120 patients met the criteria were included， with 60 cases in each group. Total response rate of observation group （88.3％） was significantly better than that of control group （73.3％）， with statistical significance （P＜0.05）. After 1， 3， 6 months of treatment， CSS score， hematoma volume， the serum levels of hs-CRP， MMP-9， IL-6 and TNF-α in 2 groups were significantly decreased， while ADL score was increased significantly； the improvement of above indexes in observation group was significantly better than in control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. The recurrence rate of control group （13.3％） was significantly higher than that of observation group （3.3％）， with statistical significance （P＜0.05）. CONCLUSIONS： Daily dose of shows atorvastatin 40 mg better therapeutic efficacy and lower recurrence rate in the treatment of CSDH with good safety. |
| 期刊： | 2017年第28卷第5期 |
| 作者： | 周宇，陈淳，邓发斌，李元斌，郭川 |
| AUTHORS： | ZHOU Yu，CHEN Chun，DENG Fabin，LI Yuanbin，GUO Chuan |
| 关键字： | 阿托伐他汀；慢性硬膜下血肿；炎症因子；临床疗效；复发率；安全性 |
| KEYWORDS： | Atorvastatin； Chronic subdural hematoma； Inflammatory factor； Clinical efficacy； Recurrence rate； Safety |
| 阅读数： | 616 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
